SunTrust Banks, Inc. restated their buy rating on shares of Stryker Corporation (NYSE:SYK) in a research note released on Monday, October 2nd. The firm currently has a $161.00 price objective on the medical technology company’s stock.

SYK has been the subject of several other research reports. Stifel Nicolaus boosted their price objective on shares of Stryker Corporation from $151.00 to $158.00 and gave the stock a buy rating in a research report on Friday, July 28th. BidaskClub lowered shares of Stryker Corporation from a buy rating to a hold rating in a report on Monday, July 31st. Canaccord Genuity reissued a buy rating and issued a $155.00 price target (down previously from $158.00) on shares of Stryker Corporation in a report on Thursday, August 24th. Argus reissued a buy rating and issued a $160.00 price target on shares of Stryker Corporation in a report on Tuesday, August 29th. Finally, Zacks Investment Research raised shares of Stryker Corporation from a hold rating to a buy rating and set a $163.00 target price for the company in a research note on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of Hold and an average target price of $146.78.

Shares of Stryker Corporation (NYSE SYK) traded up 0.09% during trading on Monday, hitting $146.69. The stock had a trading volume of 667,239 shares. The firm has a market cap of $54.87 billion, a price-to-earnings ratio of 32.74 and a beta of 0.80. The stock has a 50-day moving average of $142.96 and a 200 day moving average of $140.48. Stryker Corporation has a 12-month low of $106.48 and a 12-month high of $149.23.

Stryker Corporation (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 27th. The medical technology company reported $1.53 earnings per share for the quarter, topping the consensus estimate of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The firm had revenue of $3.01 billion during the quarter, compared to analysts’ expectations of $2.98 billion. During the same quarter in the previous year, the company posted $1.39 EPS. Stryker Corporation’s revenue was up 6.1% on a year-over-year basis. On average, analysts predict that Stryker Corporation will post $6.45 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Stryker Corporation’s (NYSE:SYK) Buy Rating Reiterated at SunTrust Banks, Inc.” was originally reported by Marea Informative and is the property of of Marea Informative. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at http://www.mareainformativa.com/stryker-corporations-syk-buy-rating-reiterated-at-suntrust-banks-inc/116983/.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Investors of record on Friday, September 29th will be given a dividend of $0.425 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.70 annualized dividend and a dividend yield of 1.16%. Stryker Corporation’s dividend payout ratio is 37.95%.

In other Stryker Corporation news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $146.36, for a total value of $731,800.00. Following the sale, the insider now owns 88,207 shares in the company, valued at $12,909,976.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Graham A. Mclean sold 1,124 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the completion of the sale, the insider now owns 8,983 shares in the company, valued at approximately $1,313,853.58. The disclosure for this sale can be found here. Company insiders own 7.40% of the company’s stock.

Institutional investors have recently modified their holdings of the business. AT Bancorp bought a new position in shares of Stryker Corporation during the first quarter valued at $202,000. Harbour Investment Management LLC bought a new position in shares of Stryker Corporation during the first quarter valued at $2,958,000. BNP Paribas Arbitrage SA raised its stake in shares of Stryker Corporation by 462.7% during the first quarter. BNP Paribas Arbitrage SA now owns 252,230 shares of the medical technology company’s stock valued at $33,206,000 after acquiring an additional 207,409 shares during the last quarter. Nelson Roberts Investment Advisors LLC raised its stake in shares of Stryker Corporation by 2.3% during the first quarter. Nelson Roberts Investment Advisors LLC now owns 56,007 shares of the medical technology company’s stock valued at $7,373,000 after acquiring an additional 1,240 shares during the last quarter. Finally, Xact Kapitalforvaltning AB raised its stake in shares of Stryker Corporation by 13.9% during the first quarter. Xact Kapitalforvaltning AB now owns 52,254 shares of the medical technology company’s stock valued at $6,879,000 after acquiring an additional 6,393 shares during the last quarter. Hedge funds and other institutional investors own 74.13% of the company’s stock.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker Corporation (NYSE:SYK)

Receive News & Stock Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related stocks with our FREE daily email newsletter.